Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival

Stage III non-small cell lung cancer (NSCLC) includes a highly heterogeneous group of patients with differences in the extent and localization of disease. Many aspects of stage III disease are controversial. The data supporting treatment approaches are often subject to a number of limitations, due to the heterogeneous patient populations involved in the trials. Furthermore, the definition of stage III disease has changed over time, and early studies were frequently inadequately powered to detect small differences in therapeutic outcome, were not randomized, or had a limited follow-up times. Major improvements in therapy, including the use of more active chemotherapy agents and refinements in radiation and surgical techniques, also limit the interpretation of earlier clinical trials. Lastly, improvements in pretreatment staging have led to reclassification of patients with relatively minimal metastatic disease as stage IV rather than stage III, leading to an apparent increase in the overall survival of both stage III and IV patients. Median overall stage III NSCLC survival ranges from 9 to 34 months. Higher survival rates are observed in younger Caucasian women with good performance status, adenocarcinoma, mutations, stage IIIA, and in patients with multidisciplinary-team-based diagnoses.

Automated summary

Stage III non-small cell lung cancer (NSCLC) presents a highly heterogeneous group of patients with diverse treatment approaches including chemotherapy, radiation, and surgery. Due to the heterogeneity of patient populations and limitations of study methods, there are controversies surrounding the treatment of stage III disease. Additionally, changes in disease definition and early research studies impact the interpretation of treatment outcomes and patient classification for stage III NSCLC.